XHANCE resources for healthcare professionals

Mechanism of Delivery and Polyp Reduction

Follow along as medication delivered by XHANCE travels through the nasal anatomy.

Journey Through the Nasal Anatomy

Follow along as medication delivered by XHANCE travels through the nasal anatomy.

Explore the mechanism of delivery for XHANCE.

The EDS^® in Action

Explore the mechanism of delivery for XHANCE.

An example of a polyp reduction from grade 2 to grade 1.

Patient 1 Endoscopy

An example of a polyp reduction from grade 2 to grade 1.

An example of polyp reduction from grade 2 to grade 0.

Patient 2 Endoscopy

An example of polyp reduction from grade 2 to grade 0.

An example of the impact of XHANCE after 6 months of use

Patient 3 Endoscopy

An example of the impact of XHANCE after 6 months of use.

Peer Insights

Allergists discuss diagnosing nasal polyps

Allergists Discuss Diagnosing Nasal Polyps

Discover the common threads that help them determine if a patient has nasal polyps.

Allergists describe their role in treating nasal polyps

Allergists Describe Their Role in Treating Nasal Polyps

Hear how they give patients relief without surgery.

Endoscopy Video Before and After

Allergists Talk About Their Experience With XHANCE

Consider why they choose XHANCE as a first-line treatment.

An ENT discusses goals of reducing nasal polyp grade and improving symptoms

An ENT’s Perspective

Hear from an ENT about treatment with XHANCE.

Patient Testimonials

Brian, 33: Diagnosed With Nasal Polypss

Brian, 33: Diagnosed With Nasal Polyps

Real XHANCE® Patient
Paid Spokesperson

ENTs talk about medical management of nasal polyps

David, 35: Diagnosed With Nasal Polyps

Real XHANCE® Patient
Paid Spokesperson

Resources for your practice

Preferred Pharmacy Finder

Preferred Pharmacy Locator

Find local specialty pharmacies within the XHANCE PPN.

English Patient Brochure

Patient Brochure

Help patients understand how XHANCE works to treat nasal polyps.

XHANCE Copay Savings Card

XHANCE Savings Card

Reduce out-of-pocket costs for eligible commercially insured patients.

Authorized Distributors

Authorized Distributors

A list of authorized distributors of XHANCE is available for pharmacists.

+

INDICATIONS

XHANCE is a corticosteroid indicated for the treatment of chronic rhinosinusitis with or without nasal polyps in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: Hypersensitivity to any ingredient in XHANCE.

WARNINGS AND PRECAUTIONS:

Local nasal adverse reactions, including epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing, can occur. Monitor
patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma until healing
has occurred.
Glaucoma and cataracts may occur with long-term use. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use XHANCE long-term.
Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after
administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.
Immunosuppression and infections can occur, including potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial,
viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue
XHANCE slowly.
Assess for decrease in bone mineral density initially and periodically thereafter.

ADVERSE REACTIONS:

Chronic rhinosinusitis without nasal polyps: The most common adverse reactions (incidence ≥ 3%) are epistaxis, headache, and nasopharyngitis.
Chronic rhinosinusitis with nasal polyps: The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal
mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DRUG INTERACTIONS: Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects

USE IN SPECIFIC POPULATIONS: Hepatic impairment. Monitor patients for signs of increased drug exposure.

Please see Full Prescribing Information pdf opensfull Prescribing Information, including Instructions for Use.